In this study, we observed neoantigens from a highly recurrent fusion gene in lung cancer showing strong immunogenic potentials (Fig. S5b), suggesting that EML4-ALK derived LAFSGIMIVY peptide may stimulate significant CD8+ TIL responses and become an valuable immunotherapeutic target for vaccine or engineered T cell therapies [26]. The gene discussed is ALK; the disease is lung cancer.